m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05328
 [1]
Non-coding RNA piRNA-30473 WTAP  lncRNA       miRNA   circRNA Direct Enhancement m6A modification HK2 HK2 WTAP Methylation : m6A sites
m6A Modification:
m6A Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
m6A Target Hexokinase-2 (HK2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator piR-30473 piRNA View Details
Regulated Target Pre-mRNA-splicing regulator WTAP (WTAP) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary piR-30473 exerts its oncogenic role through a mechanism involving the upregulation of WTAP, an m6A mRNA methylase, and thus enhances the global m6A level. WTAP increases the expression of its critical target gene, Hexokinase-2 (HK2), by enhancing the HK2 m6A level, thereby promoting the progression of DLBCL.
Responsed Disease Diffuse large B-cell lymphomas ICD-11: 2A81
 Disease Info 
In-vivo Model Four-week-old female nonobese diabetic Prkdcscid Il2rgtm1/Bcgen (NSG) mice weighing 10 to 15 g were purchased from Biocytogen Company and fed in the specific pathogen-free barrier system. Mice were subcutaneously injected in the left flank with 106 SU-DH-L8 cells in 50% Matrigel (Corning).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Hexokinase-2 (HK2) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name VDA-1102 Phase 2 [2]
MOA Modulator
External Link
TTD: D06QBX
2A81: Diffuse large B-cell lymphomas 93 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Glofitamab Approved [3]
Synonyms
Glofitamab
    Click to Show/Hide
External Link
TTD: DKF7G0
 Compound Name Epcoritamab Approved [4]
External Link
TTD: DB4M9J
 Compound Name Loncastuximab tesirine Approved [5]
External Link
TTD: D8L5PA
 Compound Name Pozelimab Approved [6]
Synonyms
REGN3918
    Click to Show/Hide
External Link
TTD: D4XBR9
 Compound Name Ocrelizumab Approved [7]
Synonyms
Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
    Click to Show/Hide
External Link
TTD: D0YV4F
 Compound Name Ofatumumab Phase 3 [8]
Synonyms
Arzerra (TN)
    Click to Show/Hide
External Link
TTD: D0Y8ZN
 Compound Name Tafasitamab Approved [9]
Synonyms
Xmab 5574/MOR208
    Click to Show/Hide
External Link
TTD: D0R3PY
 Compound Name Umbralisib Phase 2/3 [10]
Synonyms
RP5264; TGR-1202
    Click to Show/Hide
External Link
CID: 72950888
TTD: D0O8SJ
DrugBank: DB14989
 Compound Name Lisocabtagene maraleucel Approved [11]
Synonyms
JCAR017
    Click to Show/Hide
External Link
TTD: D0M4WU
 Compound Name Durvalumab Approved [12]
External Link
TTD: D0LS9E
 Compound Name Blinatumomab Phase 2/3 [12]
Synonyms
AMG 103; Blincyto
    Click to Show/Hide
External Link
TTD: D0K4RK
 Compound Name Tisagenlecleucel Application submitted [12]
Synonyms
Tisagenlecleucel-T
    Click to Show/Hide
External Link
TTD: D0IM6T
 Compound Name Axicabtagene ciloleucel Approved [7]
External Link
TTD: D0DK5R
 Compound Name Ibrutinib Phase 3 [12]
Synonyms
PCI-32765; Ibrutinib (BTK inhibitor)
    Click to Show/Hide
External Link
CID: 24821094
TTD: D09KTS
DrugBank: DB09053
 Compound Name Pembrolizumab Approved [12]
External Link
TTD: D08ANZ
 Compound Name Polatuzumab vedotin Approved [13]
External Link
TTD: D05QOL
 Compound Name Nivolumab Approved [12]
External Link
TTD: D00GOV
 Compound Name Tazemetostat Approved [12]
Synonyms
EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
    Click to Show/Hide
External Link
CID: 66558664
TTD: D00EQL
DrugBank: DB12887
 Compound Name ICP-022 Phase 2 [14]
Synonyms
Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
    Click to Show/Hide
External Link
CID: 91667513
TTD: DUTJ12
 Compound Name BI-695500 Application submitted [12]
Synonyms
Rituximab biosimilar
    Click to Show/Hide
External Link
TTD: D0X3HV
 Compound Name Abexinostat Phase 3 [12]
Synonyms
PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
    Click to Show/Hide
External Link
CID: 11749858
TTD: D0V0SL
DrugBank: DB12565
 Compound Name Pixantrone Phase 3 [15]
Synonyms
Pixuvri (TN)
    Click to Show/Hide
External Link
CID: 134019
TTD: D0Q4OW
DrugBank: DB06193
 Compound Name Enzastaurin Phase 3 [12]
Synonyms
LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
    Click to Show/Hide
External Link
CID: 176167
TTD: D0I6VU
DrugBank: DB06486
 Compound Name Adcetris Phase 3 [16]
External Link
TTD: D0F4IM
 Compound Name CC-486 Phase 3 [12]
Synonyms
AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
    Click to Show/Hide
External Link
CID: 9840076
TTD: D09NTC
 Compound Name GP2013 Phase 3 [16]
External Link
TTD: D07CPM
 Compound Name Telcyta canfosfamide Phase 3 [17]
External Link
TTD: D06BGO
 Compound Name VR876 Phase 3 [18]
External Link
TTD: D04EVE
 Compound Name Selinexor Phase 3 [19]
Synonyms
Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
    Click to Show/Hide
External Link
CID: 71481097
TTD: D00LNW
DrugBank: DB11942
 Compound Name Zilovertamab vedotin Phase 2/3 [20]
Synonyms
MK-2140
    Click to Show/Hide
External Link
TTD: D3YJZ7
 Compound Name MOR-208 Phase 2/3 [19]
Synonyms
XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor
    Click to Show/Hide
External Link
TTD: D02CYL
 Compound Name MT-3724 Phase 2 [21]
External Link
TTD: DZNH43
 Compound Name Plamotamab Phase 2 [22]
Synonyms
XmAb 13676
    Click to Show/Hide
External Link
TTD: DLM8G6
 Compound Name PF-07901801 Phase 2 [23]
Synonyms
maplirpacept
    Click to Show/Hide
External Link
TTD: D6SJ0B
 Compound Name DPX Survivac Phase 2 [24]
External Link
TTD: D5T3OY
 Compound Name Naratuximab emtansine Phase 2 [25]
Synonyms
DEBIO 1562
    Click to Show/Hide
External Link
TTD: D2R0UM
 Compound Name CD20 CAR T cells Phase 2 [26]
External Link
TTD: D0Y3HP
 Compound Name Baltaleucel-T Phase 2 [16]
External Link
TTD: D0WK1M
 Compound Name SGN-CD19A Phase 2 [27]
Synonyms
Denintuzumab mafodotin
    Click to Show/Hide
External Link
CID: 86278355
TTD: D0UT5A
 Compound Name DCDS-4501A Phase 2 [28]
External Link
TTD: D0PA1B
 Compound Name Cobomarsen Phase 1 [12]
Synonyms
MRG-106
    Click to Show/Hide
External Link
TTD: D0P9XM
 Compound Name CD19 CAR T cells Phase 2 [26]
External Link
TTD: D0L5HM
 Compound Name IMO-8400 Phase 2 [19]
Synonyms
Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M
    Click to Show/Hide
External Link
CID: 119058029
TTD: D0I0XF
 Compound Name CTL019 Phase 2 [29]
External Link
TTD: D0I0UM
 Compound Name CART-19 Phase 1 [30]
External Link
TTD: D0G4IW
 Compound Name BI-836826 Phase 2 [12]
External Link
TTD: D09WKM
 Compound Name Pidilizumab Phase 2 [31]
Synonyms
CT-011
    Click to Show/Hide
External Link
TTD: D09MRL
 Compound Name INCB50465 Phase 2 [12]
External Link
TTD: D07RHP
 Compound Name PNT-2258 Phase 2 [19]
External Link
TTD: D07ACL
 Compound Name TAK-659 Phase 2 [12]
External Link
CID: 53252276
TTD: D06KTJ
 Compound Name DEBIO 1562 Phase 2 [12]
Synonyms
MGN529
    Click to Show/Hide
External Link
TTD: D04SQO
 Compound Name Denintuzumab mafodotin Phase 2 [12]
External Link
TTD: D01QMK
 Compound Name Coltuximab ravtansine Phase 2 [12]
External Link
TTD: D00UNK
 Compound Name MGCD-0103 Phase 2 [19]
Synonyms
Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
    Click to Show/Hide
External Link
CID: 9865515
TTD: D00FHR
DrugBank: DB11830
 Compound Name CX2029 Phase 1/2 [32]
External Link
TTD: DZ1F3N
 Compound Name GEN3013 Phase 1/2 [33]
External Link
TTD: D9OMQ3
 Compound Name ALLO-501A Phase 1/2 [34]
External Link
TTD: D1HID7
 Compound Name CD19 CAR T Cells Phase 1/2 [35]
External Link
TTD: D0Z8GD
 Compound Name Anti-CD20-CAR vector-transduced autologous T cells Phase 1/2 [36]
External Link
TTD: D0V6VD
 Compound Name MAK683 Phase 1/2 [12]
Synonyms
XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663
    Click to Show/Hide
External Link
CID: 121412508
TTD: D0UO0C
 Compound Name JCAR014 Phase 1 [37]
External Link
TTD: D0U0BN
 Compound Name Anti-CD20 CAR-T cells Phase 1/2 [38]
External Link
TTD: D0MA4O
 Compound Name PCAR-019 Phase 1/2 [39]
External Link
TTD: D0M0CO
 Compound Name Anti-CD19-CAR PBL Phase 1/2 [40]
External Link
TTD: D0J3DN
 Compound Name KTE-C19 CAR Phase 1/2 [41]
External Link
TTD: D0G5WV
 Compound Name SNS01-T Phase 1/2 [42]
External Link
TTD: D0F8SW
 Compound Name CD19.CAR-T cells Phase 1/2 [43]
External Link
TTD: D0EH1J
 Compound Name CUDC-907 Phase 1 [44]
Synonyms
1339928-25-4; Fimepinostat; CUDC 907; UNII-3S9RX35S5X; CUDC907; 3S9RX35S5X; CHEMBL3622533; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; Fimepinostat [USAN]; PI3K/HDAC Inhibitor centn; MLS006010994; SCHEMBL1284705; GTPL8952; KS-00000TDO; EX-A742; AOB6775; DTXSID90712307; MolPort-023-293-550; JOWXJLIFIIOYMS-UHFFFAOYSA-N; HMS3656H04; BCP06870; s2759; BDBM50188961; 2341AH; ZINC73488511; ABP001045; AKOS026750340; SB16569; CUDC-907 (PI3K/HDAC Inhibi
    Click to Show/Hide
External Link
CID: 54575456
TTD: D0E6UZ
DrugBank: DB11891
 Compound Name Betalutin Phase 1 [12]
External Link
CID: 131704322
TTD: D0B9XW
DrugBank: DB12227
 Compound Name Anti-CD19/22-CAR vector-transduced T cells Phase 1/2 [45]
External Link
TTD: D08JTI
 Compound Name JCAR017 Phase 1 [46]
External Link
TTD: D08BPS
 Compound Name Anti-CD19 CAR-T cells Phase 1/2 [47]
External Link
TTD: D05LIH
 Compound Name Anti-CD19-CAR vector-transduced T cells Clinical trial [48]
External Link
TTD: D03UNT
 Compound Name AUTO3 Phase 1/2 [49]
External Link
TTD: D02ONA
 Compound Name Vmab + Y-90 Emab Phase 1b [50]
External Link
TTD: D0Q6IF
 Compound Name Iomab-ACT Phase 1 [51]
External Link
TTD: DZ7OC3
 Compound Name CD19t-haNK Phase 1 [52]
External Link
TTD: DV3ZI0
 Compound Name KITE-363 Phase 1 [53]
External Link
TTD: DI6BK9
 Compound Name PF-06821497 Phase 1 [54]
Synonyms
UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD
    Click to Show/Hide
External Link
CID: 118572065
TTD: DI1L7M
DrugBank: DB14799
 Compound Name AMG 562 Phase 1 [55]
External Link
TTD: D2PFY3
 Compound Name Veltuzumab/epratuzumab Y-90 Phase 1 [56]
External Link
TTD: D0V0YA
 Compound Name LIlotomab satetraxetan Phase 1 [16]
External Link
TTD: D0S9EK
 Compound Name Retroviral vector-transduced autologous T cells to express CD22-specific CARs Phase 1 [57]
External Link
TTD: D0PO0L
 Compound Name YTB323 Phase 1 [58]
External Link
TTD: D0MWS2
 Compound Name ASP3026 Phase 1 [59]
Synonyms
1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; MGGBYMDAPCCKCT-UHFFFAOYSA-N; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; QCR-144; EX-A140; DTXSID90149038; AOB6601; MolPort-028-720-342; BCP06436; 2229AH; ZINC68120928; s8054
    Click to Show/Hide
External Link
CID: 25134326
TTD: D09GEK
DrugBank: DB12729
 Compound Name ME-401 Phase 1 [12]
External Link
TTD: D08WLY
 Compound Name Human CD19 targeted T Cells Phase 1 [60]
External Link
TTD: D08LLB
 Compound Name CC-122 Phase 1 [12]
Synonyms
1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
    Click to Show/Hide
External Link
CID: 24967599
TTD: D03QZJ
DrugBank: DB14857
 Compound Name Anti-CD19/20-CAR vector-transduced T cells Clinical trial [61]
External Link
TTD: D0NL9N
 Compound Name DCDT-2980S Discontinued in Phase 2 [62]
External Link
TTD: D0EI1U
 Compound Name IM0-8400 Discontinued in Phase 1/2 [63]
External Link
TTD: D0H4XV
 Compound Name Dacetuzumab Terminated [64]
Synonyms
SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789
    Click to Show/Hide
External Link
TTD: D0PU8Z
 Compound Name WHI-P154 Investigative [65]
External Link
CID: 3795
TTD: D0E5IP
References
Ref 1 piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021 Mar 25;137(12):1603-1614. doi: 10.1182/blood.2019003764.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309
Ref 4 ClinicalTrials.gov (NCT04628494) A Phase 3 Trial of Epcoritamab in R/R DLBCL. U.S. National Institutes of Health.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761339
Ref 7 2017 FDA drug approvals. Nat Rev Drug Discov. 2018 Feb;17(2):81-85. doi: 10.1038/nrd.2018.4. Epub 2018 Jan 19.
Ref 8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6778).
Ref 9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 10 ClinicalTrials.gov (NCT02793583) Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL). U.S. National Institutes of Health.
Ref 11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
Ref 12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 14 ClinicalTrials.gov (NCT04438005) A Study of ICP-022 in Patients With R/R DLBCL (DLBCL). U.S. National Institutes of Health.
Ref 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7544).
Ref 16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 17 Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.Eur J Cancer. 2009 Sep;45(13):2324-32.
Ref 18 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040695)
Ref 19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 20 ClinicalTrials.gov (NCT05139017) A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003). U.S.National Institutes of Health.
Ref 21 ClinicalTrials.gov (NCT03488251) PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
Ref 22 ClinicalTrials.gov (NCT05328102) A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. U.S.National Institutes of Health.
Ref 23 ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
Ref 24 ClinicalTrials.gov (NCT02323230) A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL. U.S. National Institutes of Health.
Ref 25 ClinicalTrials.gov (NCT02564744) Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL. U.S. National Institutes of Health.
Ref 26 ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
Ref 27 ClinicalTrials.gov (NCT02855359) Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma. U.S. National Institutes of Health.
Ref 28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034127)
Ref 29 ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7692).
Ref 32 ClinicalTrials.gov (NCT03543813) A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). U.S.National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT04416984) A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL). U.S.National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
Ref 36 ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Ref 37 ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ref 38 ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
Ref 39 ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Ref 40 ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Ref 41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039436)
Ref 42 ClinicalTrials.gov (NCT01435720) Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL). U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
Ref 44 Clinical pipeline report, company report or official report of Curis.
Ref 45 ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Ref 46 ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Ref 47 ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Ref 48 ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Ref 49 ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
Ref 50 Clinical pipeline report, company report or official report of Immunomedics.
Ref 51 ClinicalTrials.gov (NCT04512716) Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT04989803) A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma. U.S.National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT03460977) PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma. U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT03571828) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma. U.S. National Institutes of Health.
Ref 56 Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014 Nov;99(11):1738-45.
Ref 57 ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
Ref 58 ClinicalTrials.gov (NCT03960840) CD19-specific CAR-T Cells in CLL/SLL and DLBCL. U.S. National Institutes of Health.
Ref 59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740).
Ref 60 ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Ref 61 ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027651)
Ref 63 Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
Ref 64 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. doi: 10.1517/14728210902791605.
Ref 65 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.